Mount Sinai Tisch Cancer Center

  1. Home
2 doctors

Research

Cancer Clinical Investigation
Cancer Immunology
Cancer Mechanisms
Cancer Prevention and Control

Research

The Mount Sinai Tisch Cancer Center is a National Cancer Institute-Designated Comprehensive Cancer Center with a mission to accelerate the prevention and treatment of cancer and improve the lives of cancer patients and their families in our communities. We have cultivated collaborative research programs that aim to translate discoveries into new therapies and develop novel prevention and care delivery strategies. We continually give priority to cancers that most affect the patient in our community.

With key funding through our National Cancer Institute Cancer Center Support Grant, we foster a dynamic team of scientists, clinical investigators, and administrators, all of whom create the research infrastructure needed to spur new cancer breakthroughs.

Funding Opportunities

Through our annual Developmental Fund Awards, provide support for pilot projects focused on translational and collaborative research between our cancer research programs.

An independent, dedicated Developmental Fund Award Committee oversees the selection process. On an annual basis, the request for application is created by the Develomental Fund Award Committee Chair, Stuart Aaronson, MD, and emailed to current members. The awards support translational and/or epidemiological projects that represent inter- and intra-collaborations between our members.

Prior to a project account being established, the project must comply with internal and regulatory approval processes. Scientific progress is monitored through a mid-year progress report, which is reviewed by the Committee Chair, and a final report is required. No-cost extensions can be requested, but justification is required.

Research Programs

Cancer Mechanisms: The Cancer Mechanisms Program aims to better understand cancer cell development and proliferation, and to identify therapeutic approaches that target cancer cell vulnerabilities.  

Cancer Prevention and Control: The Cancer Prevention and Control Program works to reduce the burden of cancer incidence, mortality, and risk factors.

The Mount Sinai Tisch Cancer Center 2025 Developmental Fund Awardees 

Zeynep Gümüş, PhD (Cancer Prevention and Control) and Elvin Wagenblast, PhD (Cancer Mechanisms):
Decoding Lymphoid Clonal Hematopoiesis Mechanisms and Clinical Risk 

Read Newsletter Make a Gift Discover Careers

Research Programs

Cancer Clinical Investigation

The Cancer Clinical Investigation Program develops new treatment approaches to cancer by translating discoveries into therapeutic trials.

Cancer Immunology

The Cancer Immunology Program identifies mechanisms underlying the suppression of anti-tumor immunity in order to inform the development of effective immunotherapies.

Cancer Mechanisms

The Cancer Mechanisms Program aims to better understand the biology of cancer cell development and proliferation, and to identify therapeutics that target biological pathways.

Cancer Prevention and Control

The Cancer Prevention and Control Program works to reduce the burden of cancer incidence, mortality, and disparities in cancer risks and outcomes.

The Tisch Cancer Institute 2025 Developmental Fund Awardees

Ernesto Guccione and Alessandro Lagana

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Carousel Background Image 2

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Carousel Background Image 2

Zeynep Gümüş, PhD (Cancer Prevention and Control) and Elvin Wagenblast, PhD (Cancer Mechanisms): Decoding Lymphoid Clonal Hematopoiesis

Mechanisms and Clinical Risk

Ernesto Guccione and Alessandro Lagana

Ernesto Guccione, PhD (Cancer Mechanisms) and Alessandro Lagana, PhD (Cancer Clinical Investigation)

Dissecting the Impact of DIS3 Mutations in Multiple Myeloma

Zeynep Gümüş and Elvin Wagenblast

Zeynep Gümüş, PhD (Cancer Prevention and Control) and Elvin Wagenblast, PhD (Cancer Mechanisms): Decoding Lymphoid Clonal Hematopoiesis

Mechanisms and Clinical Risk

Igor Bado and Yelena Ginzburg

Igor Bado, PhD (Cancer Mechanisms) and Yelena Ginzburg, MD (Cancer Clinical Investigation)

Modulatory Function of Erythroferrone on Metastatic Potential and Anemia in Breast Cancer

Discover the Latest

Test tubes
2026-02-19 00:00:00.0
Mount Sinai Study May Help Cancer Patients Keep Their Bladder
Read More
Flores
2026-02-12 00:00:00.0
Mount Sinai Study Strengthens Landmark Evidence Supporting Lung-Sparing Surgery, Offering Hope for Mesothelioma Patients
Read More
Test tubes
2026-01-27 00:00:00.0
Mount Sinai Study Finds Antibody-Producing Immune Cells Can Help Shape Cancer Immunotherapy
Read More
Bhardwaj
2026-01-22 00:00:00.0
Mount Sinai Review Maps the Path Forward for Cancer Vaccines, Highlighting Promise of Personalized and Combination Approaches
Read More
REsearcher using computer
2026-01-09 00:00:00.0
Mount Sinai Researchers Help Create Largest Immune Cell Atlas of Bone Marrow in Multiple Myeloma Patients
Read More
REsearcher using computer
2026-01-08 00:00:00.0
Mount Sinai Launches AI-Powered Clinical Trial-Matching Platform to Expand Access to Cancer Research
Read More
New York skyscraper seen from a park
2025-12-08 00:00:00.0
Mount Sinai Showcases Breast Cancer Research at the 2025 San Antonio Breast Cancer Symposium
Read More
CAR T Therapy
2025-11-12 00:00:00.0
Mount Sinai Study Reveals Why Some Myeloma Patients Stay Cancer-Free for Years After CAR T Therapy
Read More

Resources For You

Cancer Centers of Excellence
Patient Care
Residencies and Fellowships
Cancer InFocus: Explore Cancer Data in NYC

Contact Us

Mount Sinai Tisch Cancer Center

One Gustave L. Levy Place

Box 1128

New York, NY 10029-6574

Christine Ponder, PhD, MPA
Director, Research Administration

Email

Patient Information
The Clinical Research Support Unit

212-824-7391
Email